Search Results
Childhood and Adolescent Blood Cancer Facts and Statistics
Childhood and Adolescent Blood Cancers- An estimated 54,868 children and adolescents younger than 20 years in the US are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs).
- Leukemia is the most common cancer diagnosed in children and adolescents younger than 20 years and accounts for 25.4 percent of all cancer cases in this age-group.
- From 2016 to 2020, the most recent 5 years for which data are available, leukemia and lymphoma accounted for 38.4 percent of all cancer types in
Choosing a Blood Cancer Specialist or a Treatment Center
Taking an active role in making decisions regarding your treatment can have a positive effect on your health and quality of life. One of your first choices as an active participant in your care is to either select a specialist to manage your treatment or to choose a treatment center.
You may be seeking a blood cancer specialist or a treatment center because you:
A Source of Hope: Understanding Bone Marrow and Stem Cell Transplants
Imagine a community filled with families, friends, and healthcare professionals united to transform the meaning of living with blood cancer. This diverse group of people—including researchers, doctors, care partners, and healthcare teams—are bound together by hope, resilience, and a shared goal: to overcome the challenges and live longer better lives.
Bold goal, bold action
As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer, the children with blood cancer I have had the honor of knowing, and the many individuals and families who have been impacted by a blood cancer diagnosis.
Our work at The Leukemia & Lymphoma Society (LLS) has had a positive impact on so many, but we can do even more to accelerate progress for the blood cancer patients we serve.
Supporting development of RNA-targeting molecules for blood cancers
In June 2023, LLS made an equity investment in Rgenta Therapeutics to "Support development of RNA-targeting molecules for blood cancers." Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Rgenta has a proprietary platform to mine the massive genomics data to identify targetable RNA processing events and to design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. 
People with CLL are living longer than ever before, and cures are on the horizon
People with the most common type of blood cancer, chronic lymphocytic leukemia (CLL), are living longer than ever before without their disease progressing. While cures for CLL patients are still rare, survival rates have improved steadily over the last 50 years, with nearly 90 percent of people diagnosed with CLL today surviving at least five years, and most for many years longer.
4 Perspectives on How Nonprofits Help
If you want to change the world, there’s more than one way to do it. You could start in your community, helping friends and neighbors. You could also turn to a nonprofit organization—as a volunteer, donor, advocate, or even by joining the staff—to widen your impact.
We know a lot of changemakers at The Leukemia & Lymphoma Society (LLS). Passionate, amazing people who work hard to help us make life better for blood cancer patients, survivors, and their families. They know that we can make the most progress toward a world without blood cancer together.
The Collaboration and Infrastructure Program for Diversifying Blood Cancer Clinical Trials
This study will evaluate the effectiveness of two integrated initiatives aimed at enhancing enrollment of minoritized patients in blood cancer clinical trials. The first initiative aims to increase access to trials by utilizing procedures and technology that facilitate referral of patients from community sites of care to an academic cancer center, fostering physician collaboration, and supporting patient navigation.Pharmacological strategies to enhance T- and NK-cell-based therapies in blood cancers
Although they represent a major therapeutic progress for blood cancers, CAR-T cells and other T-cell based therapies are subject to eventual development of resistance to many patients. Natural killer (NK) cell-based therapies are highly active against many types of blood cancer cells which are resistant to T cells, but in our CRISPR studies death receptor signaling defects emerge as a common downstream mechanism of resistance to both T- and NK-cell therapies.
Shop Online and In-Store at Walgreens to Support LLS
The Leukemia & Lymphoma Society (LLS) and Walgreens are in your corner.
Since 2019, Walgreens has helped to raise more than $30 million for LLS and Susan G. Komen, all with a clear goal in mind: to advance research for tough-to-treat cancers and increase equitable access to care.
Supporting development of dimericons (crosslinked helix dimers) for blood cancers
In May 2023, LLS made an equity investment in Dimericon to "Support development of dimericons (crosslinked helix dimers) for blood cancers." 
The History of Leukemia
Table of contents
Because You Volunteer, Your Impact Creates a Ripple Effect
When you commit time and talent to a nonprofit’s mission – no matter how you choose to get involved – you become a volunteer, and the impact of your efforts runs far deeper than the specific project or task you work on. For example, volunteers don’t always realize that the hours they spent stocking shelves meant hundreds of families would have food for two weeks. Or that the time spent fundraising not only raised critical mission dollars but also added value upward of $1,250 to the organization’s bottom line.
“People Just Didn’t Get It”: Treating Young Adults with Cancer
Think of spring break: warm sunny skies, a refreshing drink, and hopefully, a feeling of freedom.
Volunteers: The Engine Powering LLS’s Mission
I was always aware that volunteers with The Leukemia & Lymphoma Society (LLS) drive impact for blood cancer patients and families. But it wasn’t until Thanksgiving Day 2007 that I discovered the full force of their power. My wife, Holly, had recently been diagnosed with follicular lymphoma and our family was still reeling from the news. She was feeling quite ill, and we were exhausted with worry and trying to keep life as normal as possible for our two young children.
Predisposing factors to leukemia
Table of contents:
Eating Well During Cancer Treatment
Making healthy food choices before, during, and after cancer treatment can help you feel better and stay stronger. In fact, people living with cancer who eat well and keep or achieve a healthy weight usually manage treatment side effects better. Eating well also helps the body replace blood cells and healthy tissues that may be damaged as a result of treatment.